IDYA

IDYA

USD

IDEAYA Biosciences Inc. Common Stock

$30.240+0.800 (2.717%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$29.440

Haut

$30.450

Bas

$28.840

Volume

0.19M

Fondamentaux de l'Entreprise

Capitalisation Boursière

2.7B

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.21M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $13.45Actuel $30.240Haut $33.64

Actualités Connexes

PR Newswire

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results...

Voir plus
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

Voir plus
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

Voir plus
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
Analyst Upgrades

JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences with a Overweight and raises the price target from $74 to $79.

Voir plus
JP Morgan Maintains Overweight on IDEAYA Biosciences, Raises Price Target to $79
Analyst Upgrades

Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences with a Neutral and raises the price target from $27 to $30.

Voir plus
Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $30
Analyst Upgrades

RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $41

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences with a Outperform and raises the price target from $38 to $41.

Analyst Upgrades

BTIG Reiterates Buy on IDEAYA Biosciences, Maintains $62 Price Target

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences with a Buy and maintains $62 price target.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.